TRDA News

The IPO market remained active this past week as 14 IPOs raised $6.3 billion. SPAC activity kept steady with 13 blank check IPOs raising $2.1 billion. New filers continued to pour into the IPO pipeline, with eight IPOs and seven SPACs submitting initial filings. Semiconductor foundry GlobalFoundries (GFS) priced at the high end to raise $2.6 billion at a $26...read more

Entrada Therapeutics, a preclinical biotech developing therapies for rare neuromuscular diseases, raised $182 million by offering 9.1 million shares at $20, within the range of $19 to $21. The company previously planned to offer 7.5 million shares at the same range. At pricing, Entrada commands a market value of $636 million.  Entrada aims to transform the lives of...read more

Entrada Therapeutics, a preclinical biotech developing therapies for rare neuromuscular diseases, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $150 million by offering 7.5 million shares at a price range of $19 to $21. At the midpoint of the proposed range, Entrada Therapeutics would command a fully diluted market value of $605 million. ...read more

Updated Monday, 10/25. The IPO market continues to stay busy with 15 IPOs schedule to raise $7.2 billion in the week ahead.   Semiconductor foundry GlobalFoundries (GFS) plans to raise $2.4 billion at a $24.6 billion market cap. Backed by Abu Dhabi’s Mubadala, US-based GlobalFoundries is one of the world’s leading specialty...read more